Product Description
BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the hallucinogenic effects commonly associated with 5-HT2A activation. As a prodrug of BMB-A39a, it exhibits minimal activity at the 5-HT2B receptor, ensuring a reduced risk of side effects. (Sourced from: https://brightmindsbio.com/bright-minds-biosciences-proprietary-compound-bmb-201-5-ht2c-2a-mixed-agonist-demonstrated-similar-efficacy-to-morphine-in-preclinical-pain-models/)
Mechanisms of Action: 5-HT2C Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bright Minds Biosciences
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Bright Minds Biosciences presented P0 Pain Unspecified results on 2024-10-16 for BMB-201
Highest Development Phases
Phase 0: Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/04/2025 |
News Article |
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model |